3.78
price down icon2.33%   -0.09
after-market After Hours: 3.90 0.12 +3.17%
loading
Mannkind Corp stock is traded at $3.78, with a volume of 2.06M. It is down -2.33% in the last 24 hours and up +1.07% over the past month. MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$3.87
Open:
$3.87
24h Volume:
2.06M
Relative Volume:
0.81
Market Cap:
$1.15B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
75.60
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-7.35%
1M Performance:
+1.07%
6M Performance:
-34.72%
1Y Performance:
-34.38%
1-Day Range:
Value
$3.75
$3.90
1-Week Range:
Value
$3.75
$4.13
52-Week Range:
Value
$3.51
$7.63

Mannkind Corp Stock (MNKD) Company Profile

Name
Name
Mannkind Corp
Name
Phone
818-661-5000
Name
Address
1 CASPER STREET, DANBURY, CA
Name
Employee
407
Name
Twitter
@MannKindCorp
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MNKD's Discussions on Twitter

Compare MNKD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MNKD
Mannkind Corp
3.78 1.18B 248.37M 11.74M 18.24M 0.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-16-25 Resumed H.C. Wainwright Buy
Apr-10-25 Initiated Mizuho Outperform
Feb-10-25 Initiated Wedbush Outperform
Dec-20-24 Initiated Wells Fargo Overweight
Dec-19-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Sep-09-24 Resumed Leerink Partners Outperform
Jun-13-24 Initiated Rodman & Renshaw Buy
Oct-10-23 Initiated Wedbush Outperform
May-14-21 Initiated RBC Capital Mkts Sector Perform
Dec-24-19 Initiated Oppenheimer Outperform
Oct-25-19 Initiated Cantor Fitzgerald Overweight
May-14-19 Initiated BTIG Research Buy
Mar-04-19 Initiated SVB Leerink Outperform
Feb-22-19 Initiated SVB Leerink Outperform
Feb-28-18 Downgrade Maxim Group Hold → Sell
Nov-01-17 Downgrade Maxim Group Buy → Hold
Oct-10-17 Initiated H.C. Wainwright Buy
Oct-06-17 Reiterated Maxim Group Buy
Aug-11-17 Initiated Maxim Group Buy
May-10-16 Reiterated Piper Jaffray Underweight
May-10-16 Reiterated RBC Capital Mkts Underperform
Jan-06-16 Reiterated Piper Jaffray Underweight
Jan-06-16 Reiterated RBC Capital Mkts Underperform
Nov-04-15 Downgrade RBC Capital Mkts Outperform → Underperform
Sep-09-15 Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15 Reiterated RBC Capital Mkts Outperform
May-11-15 Downgrade JP Morgan Neutral → Underweight
May-11-15 Reiterated MLV & Co Hold
Apr-16-15 Reiterated RBC Capital Mkts Outperform
View All

Mannkind Corp Stock (MNKD) Latest News

pulisher
Jul 31, 2025

Wedbush Remains Bullish on MannKind Corporation (MNKD) - Insider Monkey

Jul 31, 2025
pulisher
Jul 31, 2025

10 Penny Stocks That Will Skyrocket - Insider Monkey

Jul 31, 2025
pulisher
Jul 30, 2025

MannKind Corporation to Release Second Quarter 2025 Financial Results and Host Webcast on August 6, 2025 - Quiver Quantitative

Jul 30, 2025
pulisher
Jul 30, 2025

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025 - Stock Titan

Jul 30, 2025
pulisher
Jul 30, 2025

What makes MannKind Corporation stock price move sharplyMomentum Based Equity Trading Plans Reviewed - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

AI Tools Suggest MannKind Corporation May Outperform This WeekChart Driven High Reward Trading Setup Presented - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Why is MannKind Corporation stock attracting strong analyst attentionFree Daily Trading Room Entry - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is MannKind Corporation stock compared to the marketCapitalize on fast-moving stock opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating - Insider Monkey

Jul 28, 2025
pulisher
Jul 26, 2025

How MannKind Corporation stock performs during market volatilityCapital Safe Smart Trades - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What drives MannKind Corporation stock priceFree Stock Selection - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 23, 2025

MannKind stock price target lowered to $8 at RBC Capital on model updates - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about MannKind Corporation stockLightning-fast capital gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey

Jul 22, 2025
pulisher
Jul 19, 2025

MannKind Corporation Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

MannKind (NASDAQ:MNKD) Upgraded at HC Wainwright - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

Mannkind director Binder sells $296945 in shares By Investing.com - Investing.com India

Jul 18, 2025
pulisher
Jul 17, 2025

Mannkind director Binder sells $296945 in shares - Investing.com

Jul 17, 2025
pulisher
Jul 16, 2025

H.C. Wainwright assumes coverage on MannKind stock with Buy rating - Investing.com

Jul 16, 2025
pulisher
Jul 15, 2025

Why MannKind Corporation stock attracts strong analyst attentionGrowth Stock Monitor - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

High Growth Tech Stocks To Watch In The US July 2025 - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT - Insider Monkey

Jul 11, 2025
pulisher
Jul 11, 2025

13 Best Healthcare Stocks to Buy Under $10 - Insider Monkey

Jul 11, 2025
pulisher
Jul 06, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 06, 2025
pulisher
Jul 01, 2025

MannKind Corp stock hits 52-week low at $3.63 - Investing.com

Jul 01, 2025
pulisher
Jun 29, 2025

MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000 Value Index - MarketScreener

Jun 29, 2025
pulisher
Jun 27, 2025

Today In SCV History: June 27, 2014 – Valencia Company Given FDA Approval For Inhaled Insulin - KHTS Radio

Jun 27, 2025
pulisher
Jun 25, 2025

Is Day One Biopharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 24, 2025

Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - Insider Monkey

Jun 24, 2025
pulisher
Jun 23, 2025

13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey

Jun 23, 2025
pulisher
Jun 17, 2025

MannKind stock hits 52-week low at $3.70 - Investing.com

Jun 17, 2025
pulisher
Jun 11, 2025

Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga

Jun 11, 2025
pulisher
Jun 10, 2025

Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech

Jun 10, 2025
pulisher
Jun 10, 2025

MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

MannKind to present inhaled insulin study at ADA event - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada

Jun 05, 2025

Mannkind Corp Stock (MNKD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):